S Singhal

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. ncbi request reprint Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse
    S Singhal
    Leukaemia Unit, Royal Marsden Hospital, Surrey, UK
    Leuk Lymphoma 32:505-12. 1999
  2. ncbi request reprint Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling
    S Singhal
    Leukaemia Unit, Royal Marsden Hospital, Surrey, UK
    Leuk Lymphoma 34:287-94. 1999
  3. ncbi request reprint Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission
    S Singhal
    Royal Marsden Hospital, Surrey, UK
    Bone Marrow Transplant 31:889-95. 2003
  4. ncbi request reprint Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria
    B Sirohi
    Leukaemia and Myeloma Units, Royal Marsden NHS Trust, Sutton, Surrey, UK
    Bone Marrow Transplant 28:29-37. 2001
  5. ncbi request reprint An elective single autograft with high-dose melphalan: single-center study of 451 patients
    B Sirohi
    Leukaemia and Myeloma Units, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
    Bone Marrow Transplant 36:19-24. 2005
  6. pmc Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma
    B Sirohi
    Leukaemia Unit, Royal Marsden NHS Trust, Surrey, UK
    Br J Cancer 85:325-32. 2001
  7. ncbi request reprint High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission
    J Mehta
    Leukaemia Unit, The Royal Marsden Hospital, Surrey, UK
    Bone Marrow Transplant 33:1107-14. 2004
  8. ncbi request reprint Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial
    R Powles
    Leukaemia Unit, Royal Marsden Hospital, and Institute of Cancer Research, Sutton, Surrey, UK
    Lancet 355:1231-7. 2000
  9. ncbi request reprint The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy
    J Mehta
    Leukaemia Unit, Royal Marsden Hospital, Surrey, UK
    Leuk Lymphoma 34:553-60. 1999
  10. ncbi request reprint Renal dysfunction following autologous bone marrow transplantation in adult patients with acute leukemia
    P Glynne
    Leukaemia Unit, Royal Marsden Hospital, Surrey, UK
    Acta Oncol 35:709-12. 1996

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse
    S Singhal
    Leukaemia Unit, Royal Marsden Hospital, Surrey, UK
    Leuk Lymphoma 32:505-12. 1999
    ....
  2. ncbi request reprint Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling
    S Singhal
    Leukaemia Unit, Royal Marsden Hospital, Surrey, UK
    Leuk Lymphoma 34:287-94. 1999
    ..The incidence of long-term liver and kidney dysfunction measured by serum bilirubin and creatinine is low...
  3. ncbi request reprint Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission
    S Singhal
    Royal Marsden Hospital, Surrey, UK
    Bone Marrow Transplant 31:889-95. 2003
    ..If an autograft is not feasible because of nonavailability of autologous cells or very advanced disease, PMRDT is a potential alternative...
  4. ncbi request reprint Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria
    B Sirohi
    Leukaemia and Myeloma Units, Royal Marsden NHS Trust, Sutton, Surrey, UK
    Bone Marrow Transplant 28:29-37. 2001
    ....
  5. ncbi request reprint An elective single autograft with high-dose melphalan: single-center study of 451 patients
    B Sirohi
    Leukaemia and Myeloma Units, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
    Bone Marrow Transplant 36:19-24. 2005
    ..009). EFS was also longer if beta-2-microglobulin was <3.5 mg/l (P=0.0056) and patients were <60 years of age (P=0.033). We conclude that with a single planned autograft, patients with myeloma have an excellent outcome...
  6. pmc Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma
    B Sirohi
    Leukaemia Unit, Royal Marsden NHS Trust, Surrey, UK
    Br J Cancer 85:325-32. 2001
    ....
  7. ncbi request reprint High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission
    J Mehta
    Leukaemia Unit, The Royal Marsden Hospital, Surrey, UK
    Bone Marrow Transplant 33:1107-14. 2004
    ..These data show that a high-dose melphalan-based autograft is safe and could be widely applicable in ALL in first remission, and that maintenance chemotherapy very likely contributes to improved outcome of autografted ALL patients...
  8. ncbi request reprint Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial
    R Powles
    Leukaemia Unit, Royal Marsden Hospital, and Institute of Cancer Research, Sutton, Surrey, UK
    Lancet 355:1231-7. 2000
    ..Autologous transplantation with peripheral blood stem cells (PBSC) results in faster haematopoietic-cell repopulation than with bone marrow. We prospectively compared bone marrow and PBSC for allogeneic transplantation...
  9. ncbi request reprint The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy
    J Mehta
    Leukaemia Unit, Royal Marsden Hospital, Surrey, UK
    Leuk Lymphoma 34:553-60. 1999
    ..The addition of idarubicin to high-dose cytarabine and etoposide does not appear to improve CR rates. A different treatment strategy may be needed to improve CR rates for patients with non-favorable karyotypes...
  10. ncbi request reprint Renal dysfunction following autologous bone marrow transplantation in adult patients with acute leukemia
    P Glynne
    Leukaemia Unit, Royal Marsden Hospital, Surrey, UK
    Acta Oncol 35:709-12. 1996
    ..We conclude that clinically significant renal dysfunction is an uncommon long-term complication of ABMT, and should not be a concern in recommending this therapy to eligible patients...
  11. ncbi request reprint Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
    J Mehta
    Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK
    Bone Marrow Transplant 29:853-9. 2002
    ..We conclude that ABO incompatibility may influence relapse rates and survival favorably after allogeneic BMT. It is not known if this holds true for allogeneic blood stem cell transplants...
  12. ncbi request reprint Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
    S Singhal
    Myeloma Unit, The Royal Marsden Hospital, Surrey, UK
    Bone Marrow Transplant 30:673-9. 2002
    ..Myeloma patients should not be disqualified from an autograft based upon lack of response to induction chemotherapy...
  13. doi request reprint The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients
    B Sirohi
    Leukaemia Unit, The Royal Marsden Hospital, Surrey, UK
    Bone Marrow Transplant 42:105-12. 2008
    ..0001). Maintenance chemotherapy intensity was an independent determinant of outcome in Cox analysis. Maintenance chemotherapy after autotransplantation reduces relapse and improves outcome in adult patients with ALL...
  14. ncbi request reprint Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow transplantation
    J Mehta
    Royal Marsden Hospital, Sutton, Surrey, UK
    Leuk Lymphoma 26:83-8. 1997
    ..We recommend adoption of these or similar prophylactic measures for BMT in CLL as a baseline which can be modified if new infections are identified and according to individual needs...
  15. pmc Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma
    N Raje
    Myeloma Unit, Royal Marsden Hospital, Sutton, UK
    Br J Cancer 75:1684-9. 1997
    ..3% in the ABMT arm compared with 40% in the PBSCT patients (P = NS). Thus, PBSCT patients had a faster engraftment and a shorter stay in hospital than ABMT; the survival outcome and probability of relapse was the same for both groups...
  16. ncbi request reprint Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia
    S Singhal
    Royal Marsden Hospital, Surrey, UK
    Bone Marrow Transplant 29:291-5. 2002
    ....